Additional Hetero Ring Is Attached Directly Or Indirectly To The Bicyclo Ring System By Nonionic Bonding Patents (Class 514/259.41)
-
Publication number: 20110112116Abstract: Methods are provided for partial aortic obstruction for cerebral perfusion augmentation in patients suffering from global or focal cerebral ischemia. Alternatively, the methods can be used to partially obstruct aortic blood flow to condition the spinal cord to secrete neuroprotective agents prior to abdominal aortic aneurysm repair. Partial obstruction of a vessel can be accomplished by a device comprising an elongate catheter and a distally mounted expandable member. The expandable member may comprise one or two balloons. Other medical devices, such as an angioplasty, stent, or atherectomy catheter, can be inserted distal the expandable member to provide therapeutic intervention.Type: ApplicationFiled: January 19, 2011Publication date: May 12, 2011Inventor: NIKHILESH N. SINGH
-
Publication number: 20110105466Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: November 4, 2009Publication date: May 5, 2011Inventors: Timothy L. Ramsey, Mark D. Brennan
-
Publication number: 20110105469Abstract: Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: November 3, 2010Publication date: May 5, 2011Applicant: Suregene, LLCInventors: Timothy L. Ramsey, Mark D. Brennan
-
Publication number: 20110105536Abstract: The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides a method for treating psychiatric patients in need of a switching treatment to paliperidone palmitate in a sustained release formulation.Type: ApplicationFiled: November 1, 2010Publication date: May 5, 2011Inventors: Peter H. Lewyn-Briscoe, Cristiana Gassmann-Mayer, Srihari Gopal, David W. Hough, Bart M.M. Remmerie, Mahesh N. Samtani
-
Publication number: 20110105468Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: August 18, 2010Publication date: May 5, 2011Inventors: Timothy L. Ramsey, Mark D. Brennan
-
Publication number: 20110104110Abstract: The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.Type: ApplicationFiled: August 27, 2008Publication date: May 5, 2011Inventors: Gopinadhan N. Anikumar, Frank Bennett, Tin-Yau Chan, Kevin X. Chen, Mousumi Sannigrahi, Francisco Velazquez, Srikanth Venkatraman, Qingbei Zeng, Jose S. Duca, Charles A. Lesburg, Joseph A. Kozlowski, F. George Njoroge, Stuart B. Rosenblum, Neng-Yang Shih
-
Publication number: 20110106006Abstract: A device for sustained delivery of a poorly water soluble drug is described. A drug reservoir within the device, when in operation, contains an aqueous suspension of the drug mixed with a suspension of an excipient that, in one embodiment, generates acidic groups for a sustained period of time to maintain a desired pH in the aqueous suspension that in turn provides a constant concentration of a soluble form of the drug.Type: ApplicationFiled: March 11, 2010Publication date: May 5, 2011Inventors: Francis J. Martin, Ling-Ling Kang
-
Publication number: 20110105467Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.Type: ApplicationFiled: August 18, 2010Publication date: May 5, 2011Inventors: TIMOTHY L. RAMSEY, MARK D. BRENNAN
-
Publication number: 20110092463Abstract: There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a compound that inhibits the formation and/or action of angiotensin II, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in atherosclerosis and related conditions.Type: ApplicationFiled: April 3, 2009Publication date: April 21, 2011Inventors: Johan Raud, Carl-Johan Dalsgaard
-
Publication number: 20110086104Abstract: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step.Type: ApplicationFiled: December 14, 2010Publication date: April 14, 2011Applicant: Alkermes, Inc.Inventors: Michael E. Rickey, J. Michael Ramstack, Rajesh Kumar
-
Publication number: 20110086023Abstract: The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) a mucosal adjuvant, (3) an antihistamine drug and (4) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin, a topical steroid or a leukotriene blocker.Type: ApplicationFiled: December 20, 2010Publication date: April 14, 2011Applicant: Fairfield Clinical Trials LLCInventor: Edward M. Lane
-
Publication number: 20110071167Abstract: The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.Type: ApplicationFiled: November 23, 2010Publication date: March 24, 2011Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Ashley BUSH, Colin Louis MASTERS, Penelope Jane HUGGINS, Jack Gordon PARSONS, Gaik Beng KOK, Vijaya KENCHE, Mariana EL SOUS
-
Publication number: 20110065628Abstract: The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention provides compositions and methods for treating disorders using combinations of drugs such as topiramate, ondansetron, and naltrexone.Type: ApplicationFiled: May 20, 2008Publication date: March 17, 2011Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Bankole A. Johnson, Nassima Ait-Daoud Tiouririne, Wendy J. Lynch
-
Publication number: 20110052687Abstract: The present invention provides an extended release tablet of paliperidone, comprising a) a core containing paliperidone and at least one water soluble and/or gellable polymer, b) a coating comprising at least one water insoluble or permeable polymer, and a water soluble and/or gellable polymer and optionally an enteric polymer.Type: ApplicationFiled: August 25, 2010Publication date: March 3, 2011Applicant: GLENMARK GENERICS LTDInventors: Kamal Mehta, Pankaj Shinde, Hidaytulla Aga, Rajadeep Gupta
-
Publication number: 20110053960Abstract: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.Type: ApplicationFiled: August 27, 2010Publication date: March 3, 2011Applicant: VM DISCOVERY INC.Inventor: Jay Jie-Qiang WU
-
Publication number: 20110039825Abstract: The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously ?-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C1-C4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, CF3, CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH2)m group, optionally substituted CH?CH group, optionally substType: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Applicant: Alla Chem, LLCInventors: Andrey Alexandrovich Ivashchenko, Vasilievich Ivashchenko, Yan Vadimovich Lavrovsky, Oleg Dmitrievich Mitkin, Nikolay Filippovich Savchuk, Sergey Yevgenievich Tkachenko, Ilya Matusovich Okun
-
Publication number: 20110039842Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Pharmaceutical compositions comprising a compound of formula (I) are also provided.Type: ApplicationFiled: July 2, 2009Publication date: February 17, 2011Inventors: John Joseph Deadman, Eric Dale Jones, Giang Thanh Le, David Ian Rhodes, Neeranat Theinthong, Nicholas Andrew Van de Graff, Lisa Jane Winfield
-
Publication number: 20110039834Abstract: The present invention relates to the field of life needs and more particularly to the therapeutic field. The invention relates more particularly to pharmaceutical compositions for helping the takers of addictive drugs to return to abstinence, in the form of a combination of two medicaments constituted of a partial or complete ligand of dopaminergic receptors—in particular of the D1, D2 and D3 receptors, and having direct prodopaminergic activity, and of an indirect prodopaminergic product, in the form of a pharmaceutical composition for oral, parenteral or transdermal administration. The invention also relates to a method for combating the various forms of addiction to licit or illicit drugs.Type: ApplicationFiled: February 19, 2007Publication date: February 17, 2011Applicant: TRIMARAN LIMITEDInventor: Mario Sanchez
-
Publication number: 20110027361Abstract: The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same.Type: ApplicationFiled: February 3, 2009Publication date: February 3, 2011Applicant: TORRENT PHARMACEUTICALS LTD.Inventors: Ganesan Murugesan, Jaya Abraham, Vinodkumar Gupta, Bhavesh Shah
-
Publication number: 20110027397Abstract: Disclosed are compositions that inhibit brain blood vessel leakage, compositions for treating autism spectrum disorders, methods of treating autism spectrum disorders, and methods of screening for an autism spectrum disorder.Type: ApplicationFiled: August 3, 2009Publication date: February 3, 2011Inventor: Theoharis C. THEOHARIDES
-
Publication number: 20110014304Abstract: The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.Type: ApplicationFiled: June 15, 2010Publication date: January 20, 2011Applicant: Newron Pharmaceuticals S.p.A.Inventors: Emanuela Izzo, Laura Faravelli, Elena Barbanti, Patricia Salvati
-
Publication number: 20110015212Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.Type: ApplicationFiled: June 28, 2010Publication date: January 20, 2011Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
-
Publication number: 20110009366Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.Type: ApplicationFiled: April 23, 2010Publication date: January 13, 2011Applicant: AVEXA LIMITEDInventors: Eric Dale Jones, Jonathan Alan Victor Coates, David Ian Rhodes, John Joseph Deadman, Nicholas Andrew Vandegraff, Lisa Jane Winfield, Neeranat Thienthong, William Issa, Neil Choi, Katherinie Macfarlane
-
Publication number: 20100324020Abstract: The present invention relates to a series of substituted bicyclic[3.1.0]heteroaryl amides of the Formula I, wherein A, Q, X, Y, Z and R1-R5 groups are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.Type: ApplicationFiled: August 30, 2010Publication date: December 23, 2010Inventors: Stanton F. McHardy, John A. Lowe, III
-
Publication number: 20100323887Abstract: Disclosed are compounds of Formula 1, wherein X is O or S; Y is O or S; and R1, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.Type: ApplicationFiled: January 30, 2009Publication date: December 23, 2010Applicant: E.I. DU Pont De Nemours and CompanyInventors: Caleb William Holyoke, JR., My-Hanh Thi Tong, Reed Aaron Coats, Wenming Zhang, Stephen Frederick McCann, Dominic Ming-Tak Chan
-
Publication number: 20100311719Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.Type: ApplicationFiled: August 17, 2010Publication date: December 9, 2010Inventors: Péter Literáti Nagy, Jesse Roth, Zoltán Szilvássy, Kálmán Tory, Mike Brownstein, Kálmán Takács, László Vígh, József Mandl, Balázs Sümegi, Sándor Bernáth, Attila Kolonics, Gábor Balogh, János Egri
-
Publication number: 20100310681Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.Type: ApplicationFiled: June 3, 2010Publication date: December 9, 2010Applicant: MARQUETTE UNIVERSITYInventor: Mohammadhossein Behnam Ghasemzadeh
-
Publication number: 20100303900Abstract: Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.Type: ApplicationFiled: August 13, 2010Publication date: December 2, 2010Applicant: Alkermes Controlled Therapeutics, Inc.Inventors: J. Michael Ramstack, M. Gary I. Riley, Stephen E. Zale, Joyce M. Hotz, Olufunmi L. Johnson
-
Publication number: 20100297031Abstract: This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.Type: ApplicationFiled: September 30, 2008Publication date: November 25, 2010Applicant: LABORATORIOS LESVI, S.L.Inventors: Carmen Úbeda Pérez, Ignacio Díez Martín, Pablo Pablo Alba
-
Publication number: 20100292254Abstract: The present invention related to fused pyrimidine derivatives, which are useful as Transient Receptor Potential Vanilloid 3 (TRPV3) receptors, methods of treating deseases, disorders, conditions modulated by TRPV3. The present invention having the formula (I) and its pharmaceutically acceptable salts thereof, and its processes thereof, wherein all variables are as described herein.Type: ApplicationFiled: January 7, 2009Publication date: November 18, 2010Applicant: GLENMARK PHARMACEUTICALS, S.A.Inventors: V S, Prasadarao Lingam, Abraham Thomas, Dattaguru Anandrao More, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Publication number: 20100292195Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: ApplicationFiled: February 13, 2008Publication date: November 18, 2010Applicant: QLT USA, INC.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Publication number: 20100292211Abstract: The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.Type: ApplicationFiled: September 10, 2008Publication date: November 18, 2010Inventor: Christian LAVEDAN
-
Publication number: 20100266655Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.Type: ApplicationFiled: February 13, 2008Publication date: October 21, 2010Applicant: QLT USA INCInventor: Eric Dadey
-
Publication number: 20100249188Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.Type: ApplicationFiled: September 10, 2008Publication date: September 30, 2010Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
-
Publication number: 20100234349Abstract: This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.Type: ApplicationFiled: September 4, 2007Publication date: September 16, 2010Inventors: Gunnar M. Olsen, Dan Peters, Bjarne H. Dahl, Jeppe Kejser Christensen, Steven Charles Loechel, Daniel B. Timmermann
-
Publication number: 20100233244Abstract: The present invention relates to a quickly decomposing oral drug preparation, for the application of active ingredient combinations for smoking withdrawal, which contains nicotine, a nicotine salt, a nicotine derivative, or a substance that reacts to nicotine, in combination with another active ingredient, and the use of such a drug preparation for the treatment of smoking withdrawal, and the use of nicotine, and/or nicotine salts or derivatives, for the production of medications for the treatment of smoking withdrawal. The active ingredient that is to be administered, in combination, for this purpose is a centrally active ingredient, preferably an antidepressant for the fighting of psychic dependency in terms of a smoking withdrawal therapy. The administration of the active ingredient combination to the patient should be handled in a simple and reliable way and should exclude side effects to a large extent.Type: ApplicationFiled: June 4, 2007Publication date: September 16, 2010Applicant: LTS Lohmann Therapie-Systeme AGInventors: Hans-Rainer Hoffmann, Reto Brändli, Frank Theobald
-
Publication number: 20100226979Abstract: Disclosed herein a taste masked pharmaceutical composition suitable for oral solid dosage form comprising adsorbate of unpleasant or objectionable tasting active pharmaceutical agents and water insoluble polymer, wherein said active is first blended with an adsorbent such as magnesium aluminium silicate to achieve partially or significantly taste masking of said active and further granulated the resultant blend with water insoluble polymer to strengthen the taste masking without affecting the release of said active.Type: ApplicationFiled: March 19, 2007Publication date: September 9, 2010Applicant: JUBILANT ORGANOSYS LIMITEDInventors: Namdev Kashid, Pradeep Chouhan, Gour Mukherji
-
Publication number: 20100210631Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital, and gastrointestinal diseases.Type: ApplicationFiled: May 14, 2008Publication date: August 19, 2010Applicant: NEWRON PHARMACEUTICALS S.P.A.Inventors: Piero Melloni, Alessandra Restivo, Emanuela Izzo, Simona Francisconi, Elena Colombo, Cibele Sabido-David
-
Patent number: 7776866Abstract: The present application describes deuterium-enriched risperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: GrantFiled: September 11, 2008Date of Patent: August 17, 2010Assignee: Protia, LLCInventor: Anthony W Czarnik
-
Publication number: 20100203104Abstract: This invention relates to an extended release formulation comprising solid risperidone, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing risperidone. The polymer is preferably made of ethylene-vinyl acetate copolymer.Type: ApplicationFiled: November 21, 2007Publication date: August 12, 2010Inventors: Wouter De Graaff, Armin Szegedi
-
Publication number: 20100189818Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: January 19, 2010Publication date: July 29, 2010Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: GUOCHUAN EMIL TSAI
-
Publication number: 20100189698Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.Type: ApplicationFiled: June 30, 2008Publication date: July 29, 2010Applicant: CLARENCEW PTY LTDInventor: Gregory Lynn Willis
-
Publication number: 20100184783Abstract: There is provided combination products comprising (a) a mast cell inhibitor, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a PPARY agonist, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in atherosclerosis and related conditions.Type: ApplicationFiled: June 25, 2008Publication date: July 22, 2010Inventors: Johan Raud, Carl-Johan Dalsgaard
-
Publication number: 20100178349Abstract: Pharmaceutical formulation in the form of agglomerates comprising A) an excipient content composed of a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of a disintegrant, c) 1-15% by weight of water-insoluble, film-forming polymers d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients the total of the components a) to e) being 100% by weight, and B) at least one active ingredient.Type: ApplicationFiled: June 3, 2008Publication date: July 15, 2010Applicant: BASF SEInventors: Karl Kolter, Michael Schönherr, Silke Gebert, Kathrin Meyer-Böhm, Angelika Maschke
-
Publication number: 20100166889Abstract: The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: LCS GROUP, LLCInventor: Louis Sanfilippo
-
Publication number: 20100168114Abstract: Methods for determining invertebrate- and insect-specific, such as mosquito-specific, residues of acetylcholinesterases are provided herein. The methods can be used to design pesticides and insecticides that are specific for the invertebrate or insect (e.g., mosquito) enzymes, resulting in reduced toxicity concerns for mammals. Compositions for inhibiting invertebrate and insect (e.g., mosquito) acetylcholinesterases and methods for preparing the same are also provided.Type: ApplicationFiled: December 18, 2009Publication date: July 1, 2010Inventor: Yuan-Ping Pang
-
Publication number: 20100168137Abstract: There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) ramatroban, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosclerosis and related conditions.Type: ApplicationFiled: December 18, 2007Publication date: July 1, 2010Inventor: Johan Raud
-
Publication number: 20100160347Abstract: The present invention relates to new pyrido[1,2-a]pyrimidin-4-one inhibitors of mast cell degranulation, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 17, 2009Publication date: June 24, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100159033Abstract: The present invention relates to new benzisoxazole modulators of D2 receptors and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 25, 2009Publication date: June 24, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manoucherhr M. Shahbaz
-
Publication number: 20100159034Abstract: The present invention relates to new pyrrolidinone inhibitors of PDE-4 activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 15, 2009Publication date: June 24, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar